Low-dose Chemotherapy Plus Antiangiogenesis Drug Has Activity In Advanced Breast Cancer
12th Dec 2005, 16:04 GMT
Chemotherapy given in low, frequent doses -- a novel strategy called "metronomic" delivery -- achieved partial shrinkage of disease in some advanced breast cancer patients when given concurrently with an angiogenesis inhibitor, report researchers from Dana-Farber Cancer Institute.
Low-dose Chemotherapy Plus Antiangiogenesis Drug Has Activity In Advanced Breast Cancer related news:
- SABCS: Dose-Dense Chemotherapy Called Safe and Effective — MedPage Today Hematology/Oncology
- Fatigue fairly uncommon after breast cancer chemo (Reuters) —
- Novartis drug helps prevent breast cancer recurrence — Pharmaceutical Business Review Online
- Fatigue fairly uncommon after breast cancer chemo — RedOrbit News - Health
- Breast cancer treatment changing — The Cancer Blog
- Aromatase inhibitor shows promise for breast cancer patients — The Cancer Blog
- Breast cancer drug may work in lung cancer — United Press International - Health Business
- Breast cancer trials set for second phase — bizjournals.com Health Care:Pharmaceuticals headlines
- SABCS: Shorter Chemotherapy Regimen Plus Taxol Reduces Breast Cancer Recurrence — MedPage Today Hematology/Oncology
- More good news - Femara helps prevent the return of breast cancer — News-Medical News Feed
Latest news from ScienceDaily Headlines: Health & Medicine:
- Scientists Discover Way To Block Growth Of Prostate Cancer Cells
- Fast Test For Low Blood Flow In Dogs Detects Early Heart Trouble
- Multiplexed Serum Markers Screening For Detection Of Pancreatic Cancer
- Researchers Writing Story Of The 'Alcoholic Lung'
- Salt Intake Is Strongly Associated With Obesity
- Australian Discovery Could Lead To New Leukemia Treatments
- Progress Made In HIV Vaccine Development
- Nanoscale Microscope Sheds First Light On Gene Repair
- Enzyme May Hold Key To New Treatment Of Diabetic Kidney Disease
- Diabetes Medication May Help Slow Progression Of Artery Wall Thickening